TY - JOUR
T1 - Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves
T2 - Insights from the VIVID registry
AU - Ribeiro, Henrique B.
AU - Rodés-Cabau, Josep
AU - Blanke, Philipp
AU - Leipsic, Jonathon
AU - Kwan Park, Jong
AU - Bapat, Vinayak
AU - Makkar, Raj
AU - Simonato, Matheus
AU - Barbanti, Marco
AU - Schofer, Joachim
AU - Bleiziffer, Sabine
AU - Latib, Azeem
AU - Hildick-Smith, David
AU - Presbitero, Patrizia
AU - Windecker, Stephan
AU - Napodano, Massimo
AU - Cerillo, Alfredo G.
AU - Abdel-Wahab, Mohamed
AU - Tchetche, DIdier
AU - Fiorina, Claudia
AU - Sinning, Jan Malte
AU - Cohen, Mauricio G.
AU - Guerrero, Mayra E.
AU - Whisenant, Brian
AU - Nietlispach, Fabian
AU - Palma, José Honório
AU - Nombela-Franco, Luis
AU - De Weger, Arend
AU - Kass, Malek
AU - Sandoli De Brito, Fabio
AU - Lemos, Pedro A.
AU - Kornowski, Ran
AU - Webb, John
AU - Dvir, Danny
N1 - Funding Information:
Conflict of interest: H.B.R. is a proctor and consultant for Edwards Lifesciences and Medtronic. J.R.C. has received research grants from Edwards Lifesciences, Medtronic, and St. Jude Medical. M.A.W. has received research grants from St. Jude and Biotronik, and is a proctor for Boston Scientific. M.G. has received research grant support and has served as proctor for Edwards Lifesciences. S.B. is a proctor and consultant for Medtronic, proctor for Boston Scientific and JenaValve. S.W. reports research grants to his institution from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic and St. Jude Medical. A.L. is a consultant for Medtronic and DirectFlow Medical. D.H.S is a proctor for Boston Scientific, St. Jude Medical, Medtronic and Edwards Lifesciences. F.N. is a consultant for Edwards Lifesciences, Medtronic, St. Jude Medical and 4Tech. V.B is a consultant for Edwards Lifesciences, Boston Scientific, Medtronic and Sorin, has received research grants from Boston Scientific. D.D. is a consultant for Edwards Lifesciences, Medtronic and St. Jude Medical. No other disclosures were reported.
Funding Information:
H.B.R. was supported by a research PhD grant [246860/2012-0] from Conselho Nacional de Desenvolvimento Científico e Tecnológico. No other funding sources were utilized.
Funding Information:
... H.B.R. was supported by a research PhD grant [246860/2012-0] from ... Conselho Nacional de Desenvolvimento Cient′ıfico e Tecnolo′gico. No ... other funding sources were utilized.
Publisher Copyright:
© The Author 2017. For permissions, please email: journals.permissions@oup.com.
PY - 2018/2/21
Y1 - 2018/2/21
N2 - Aims There are limited data on coronary obstruction following transcatheter valve-in-valve (ViV) implantation inside failed aortic bioprostheses. The objectives of this study were to determine the incidence, predictors, and clinical outcomes of coronary obstruction in transcatheter ViV procedures. Methods and results A total of 1612 aortic procedures from the Valve-in-Valve International Data (VIVID) Registry were evaluated. Data were subject to centralized blinded corelab computed tomography (CT) analysis in a subset of patients. The virtual transcatheter valve to coronary ostium distance (VTC) was determined. A total of 37 patients (2.3%) had clinically evident coronary obstruction. Baseline clinical characteristics in the coronary obstruction patients were similar to controls. Coronary obstruction was more common in stented bioprostheses with externally mounted leaflets or stentless bioprostheses than in stented with internally mounted leaflets bioprostheses (6.1% vs. 3.7% vs. 0.8%, respectively; P < 0.001). CT measurements were obtained in 20 (54%) and 90 (5.4%) of patients with and without coronary obstruction, respectively. VTC distance was shorter in coronary obstruction patients in relation to controls (3.24 ± 2.22 vs. 6.30 ± 2.34, respectively; P < 0.001). Using multivariable analysis, the use of a stentless or stented bioprosthesis with externally mounted leaflets [odds ratio (OR): 7.67; 95% confidence interval (CI): 3.14-18.7; P < 0.001] associated with coronary obstruction for the global population. In a second model with CT data, a shorter VTC distance predicted this complication (OR: 0.22 per 1 mm increase; 95% CI: 0.09-0.51; P < 0.001), with an optimal cut-off level of 4 mm (area under the curve: 0.943; P < 0.001). Coronary obstruction was associated with a high 30-day mortality (52.9% vs. 3.9% in the controls, respectively; P < 0.001). Conclusion Coronary obstruction following aortic ViV procedures is a life-threatening complication that occurred more frequently in patients with prior stentless or stented bioprostheses with externally mounted leaflets and in those with a short VTC.
AB - Aims There are limited data on coronary obstruction following transcatheter valve-in-valve (ViV) implantation inside failed aortic bioprostheses. The objectives of this study were to determine the incidence, predictors, and clinical outcomes of coronary obstruction in transcatheter ViV procedures. Methods and results A total of 1612 aortic procedures from the Valve-in-Valve International Data (VIVID) Registry were evaluated. Data were subject to centralized blinded corelab computed tomography (CT) analysis in a subset of patients. The virtual transcatheter valve to coronary ostium distance (VTC) was determined. A total of 37 patients (2.3%) had clinically evident coronary obstruction. Baseline clinical characteristics in the coronary obstruction patients were similar to controls. Coronary obstruction was more common in stented bioprostheses with externally mounted leaflets or stentless bioprostheses than in stented with internally mounted leaflets bioprostheses (6.1% vs. 3.7% vs. 0.8%, respectively; P < 0.001). CT measurements were obtained in 20 (54%) and 90 (5.4%) of patients with and without coronary obstruction, respectively. VTC distance was shorter in coronary obstruction patients in relation to controls (3.24 ± 2.22 vs. 6.30 ± 2.34, respectively; P < 0.001). Using multivariable analysis, the use of a stentless or stented bioprosthesis with externally mounted leaflets [odds ratio (OR): 7.67; 95% confidence interval (CI): 3.14-18.7; P < 0.001] associated with coronary obstruction for the global population. In a second model with CT data, a shorter VTC distance predicted this complication (OR: 0.22 per 1 mm increase; 95% CI: 0.09-0.51; P < 0.001), with an optimal cut-off level of 4 mm (area under the curve: 0.943; P < 0.001). Coronary obstruction was associated with a high 30-day mortality (52.9% vs. 3.9% in the controls, respectively; P < 0.001). Conclusion Coronary obstruction following aortic ViV procedures is a life-threatening complication that occurred more frequently in patients with prior stentless or stented bioprostheses with externally mounted leaflets and in those with a short VTC.
KW - Coronary obstruction
KW - Coronary occlusion
KW - Prior surgical bioprosthesis
KW - Transcatheter aortic valve replacement
KW - Valve-in-valve
UR - http://www.scopus.com/inward/record.url?scp=85037697129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037697129&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehx455
DO - 10.1093/eurheartj/ehx455
M3 - Article
C2 - 29020413
AN - SCOPUS:85037697129
SN - 0195-668X
VL - 39
SP - 687
EP - 695
JO - European heart journal
JF - European heart journal
IS - 8
ER -